UNSPSC 51241118: Dichlorphenamide or diclofenamide

This classification denotes a cholinergic agonist and carbonic anhydrase inhibitor with the molecular formula C6H6Cl2N2O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VVJ6673MHY, chemically known as 4,5-dichloro-m-benzenedisulfonamide but generally known as dichlorphenamide, which bears US NIH Compound Identifier 3038. European Medicines Agency schedules Dichlorphenamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07093MIG.

UNSPSC 51241118 Dichlorphenamide or diclofenamide is a Commodity code covering a carbonic anhydrase inhibitor pharmaceutical used to treat glaucoma and certain seizure disorders. State and local government procurement under this code centers on pharmaceutical supply contracts for corrections facilities, public health departments, and state hospital systems that stock this drug for inmate and patient populations. Issuing bodies are typically state departments of corrections, state departments of health, and state-operated mental health or developmental disability facilities; county jail systems and regional healthcare authorities also source this pharmaceutical when treating populations in custody or state care. The work involves direct pharmaceutical procurement, often through existing state formulary systems or cooperative purchasing agreements, rather than any manufacturing, development, or clinical services.

The source contains no recent state or local contract opportunities posted for dichlorphenamide or diclofenamide procurement. Without posted RFP, RFQ, IFB, or ITB notices in the recent-opportunities block, geographic distribution and current market activity cannot be characterized. Firms pursuing this code should monitor state procurement portals in corrections-heavy and public-health-focused states (California, Texas, Florida, New York, Illinois) for pharmaceutical supply solicitations, as these jurisdictions operate the largest public inmate and state-facility populations that require carbonic anhydrase inhibitors; however, individual opportunities are sparse and irregular, typically bundled into broader pharmaceutical supply contracts rather than issued as standalone line items.